MX2018008339A - Multimeros fc de inmunoglobulina g recombinante. - Google Patents

Multimeros fc de inmunoglobulina g recombinante.

Info

Publication number
MX2018008339A
MX2018008339A MX2018008339A MX2018008339A MX2018008339A MX 2018008339 A MX2018008339 A MX 2018008339A MX 2018008339 A MX2018008339 A MX 2018008339A MX 2018008339 A MX2018008339 A MX 2018008339A MX 2018008339 A MX2018008339 A MX 2018008339A
Authority
MX
Mexico
Prior art keywords
multimers
recombinant igg
igg
recombinant
administering
Prior art date
Application number
MX2018008339A
Other languages
English (en)
Inventor
Zuercher Adrian
Panousis Con
SPIRIG Rolf
KAESERMANN Fabian
BAZ MORELLI Adriana
Guang Chen Chao-
Original Assignee
CSL Behring Lengnau AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring Lengnau AG filed Critical CSL Behring Lengnau AG
Publication of MX2018008339A publication Critical patent/MX2018008339A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta descripción provee multimeros Fc de IgG recombinante y métodos para tratar enfermedades autoinmunes e inflamatorias mediante la administración de dichos multímeros.
MX2018008339A 2016-01-27 2017-01-27 Multimeros fc de inmunoglobulina g recombinante. MX2018008339A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP16152867 2016-01-27
EP16162166 2016-03-24
EP16195116 2016-10-21
PCT/EP2017/051757 WO2017129737A1 (en) 2016-01-27 2017-01-27 Recombinant igg fc multimers

Publications (1)

Publication Number Publication Date
MX2018008339A true MX2018008339A (es) 2018-09-17

Family

ID=57956274

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018008339A MX2018008339A (es) 2016-01-27 2017-01-27 Multimeros fc de inmunoglobulina g recombinante.

Country Status (13)

Country Link
US (1) US20190119377A1 (es)
EP (1) EP3408279A1 (es)
JP (1) JP2019511458A (es)
KR (1) KR20180100701A (es)
CN (1) CN108602857A (es)
AU (1) AU2017213117A1 (es)
BR (1) BR112018014668A2 (es)
CA (1) CA3012037A1 (es)
HK (1) HK1258166A1 (es)
MX (1) MX2018008339A (es)
RU (1) RU2018130525A (es)
SG (2) SG11201805579SA (es)
WO (1) WO2017129737A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116970061A (zh) 2016-12-22 2023-10-31 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
EP3565829A4 (en) 2017-01-09 2021-01-27 Cue Biopharma, Inc. MULTIMER POLYPEPTIDES T-LYMPHOCYTE MODULATORS AND THEIR METHODS OF USE
US20200010528A1 (en) 2017-03-15 2020-01-09 Cue Biopharma, Inc. Methods for modulating an immune response
CN112004550A (zh) * 2017-12-14 2020-11-27 康诺贝林伦瑙有限公司 用于治疗视神经脊髓炎的重组IgG Fc多聚体
EP3737689A4 (en) 2018-01-09 2021-12-01 Cue Biopharma, Inc. MULTIMERIC T CELL-MODULATING POLYPEPTIDES AND METHOD OF USING THEREOF
EP3775926A1 (en) 2018-08-30 2021-02-17 Regeneron Pharmaceuticals, Inc. Methods for characterizing protein complexes
BR112021011107A2 (pt) 2018-12-13 2021-12-14 Argenx Bvba Anticorpos para o fator de complemento humano c2b e métodos de uso
KR20220062084A (ko) * 2019-09-13 2022-05-13 체에스엘 베링 렝나우 아게 면역 복합체 매개된 콩팥 장애의 치료를 위한 재조합 IgG Fc 다량체
KR20220066075A (ko) * 2019-09-20 2022-05-23 큐 바이오파마, 인크. T-세포 조절 폴리펩타이드 및 이의 사용 방법
CA3153207A1 (en) * 2019-10-16 2021-04-22 Chugai Seiyaku Kabushiki Kaisha An antibody, a pharmaceutical composition, and a method
MX2022006703A (es) 2019-12-06 2022-07-12 CSL Behring Lengnau AG Composiciones estables de multimeros fc.
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2022056014A1 (en) 2020-09-09 2022-03-17 Cue Biopharma, Inc. Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
CN114894911B (zh) * 2022-03-18 2023-10-24 辽宁成大生物股份有限公司 一种控制牛血清产品质量方法
CN118027155B (zh) * 2024-04-15 2024-07-16 中国人民解放军军事科学院军事医学研究院 一种tpor结合肽及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013049254A1 (en) * 2011-09-26 2013-04-04 Jn Biosciences Llc Hybrid constant regions
BR112015000167B1 (pt) * 2012-07-06 2021-11-23 Genmab B.V. Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante
CN104870055A (zh) * 2012-10-17 2015-08-26 利物浦热带医学院 免疫调节蛋白
US11352414B2 (en) * 2014-03-05 2022-06-07 UCB Biopharma SRL Multimeric Fc proteins
SG11201606596PA (en) * 2014-03-05 2016-09-29 Ucb Biopharma Sprl Multimeric fc proteins

Also Published As

Publication number Publication date
RU2018130525A3 (es) 2020-05-29
CN108602857A (zh) 2018-09-28
EP3408279A1 (en) 2018-12-05
AU2017213117A1 (en) 2018-07-19
SG10201911561SA (en) 2020-02-27
CA3012037A1 (en) 2017-08-03
WO2017129737A1 (en) 2017-08-03
JP2019511458A (ja) 2019-04-25
RU2018130525A (ru) 2020-02-27
KR20180100701A (ko) 2018-09-11
HK1258166A1 (zh) 2019-11-08
BR112018014668A2 (pt) 2018-12-11
SG11201805579SA (en) 2018-08-30
US20190119377A1 (en) 2019-04-25

Similar Documents

Publication Publication Date Title
MX2018008339A (es) Multimeros fc de inmunoglobulina g recombinante.
CY1122344T1 (el) Blautia stercosis και wexlerae για χρηση στην θεραπευτικη αγωγη φλεγμονωδων και αυτοανοσων νοσων
CY1122184T1 (el) Συνθεσεις περιλαμβανουσες βακτηριακα στελεχη
CY1121473T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
CY1125136T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
CY1124013T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
CY1123381T1 (el) Συνθεσεις που περιεχουν βακτηριακα στελεχη
CY1122148T1 (el) Συνθεσεις που περιεχουν βακτηριακα στελεχη
ZA201903327B (en) Compositions and methods for the induction of cd8+ t¿cells
EA201891199A1 (ru) Композиции, содержащие бактериальные штаммы
EP3506926A4 (en) NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC PROCEDURES FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES
MX2018008515A (es) Composiciones y metodos relacionados con sistemas celulares terapeuticos multimodales para indicaciones inmunitarias.
NZ738008A (en) Tigit-binding agents and uses thereof
EA202190903A2 (ru) Молекулы, которые избирательно активируют регуляторные t-клетки, для лечения аутоиммунных заболеваний
EA201992609A1 (ru) Слитые белки, содержащие интерлейкин-2, и их применения
PH12017501522A1 (en) Antibodies to tau and uses thereof
GEP201706794B (en) Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
MX2020005567A (es) Metodos de tratamiento con asparaginasa.
SV2018005714A (es) Composiciones y metodos para disminuir la expresion de tau
EA201691521A1 (ru) Антитела к интерлейкину-21
EA201790565A1 (ru) Композиции и способы для лечения предраковых поражений кожи
MX2018002447A (es) Uso de anticuerpos anti-cd40 para el tratamiento de nefritis lupica.
MX2018007408A (es) Uso de adyuvantes para la prevencion y/o el tratamiento de enfermedades autoinmunes.
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: CSL BEHRING LENGNAU AG